President Obama Health Care Plan Has Started a Medical Revolution
Bethesda Maryland (AP ) Genomics is leading the way. There are four companies that are making major moves after President Obama Health Care Reform Act Passed. BGI a Chinese base Company with offices in North Americas, Complete Genomics, Opko Health and Gennxeix Biotech. Lets start with a Introduction of the companies.
Complete Genomics:
BGI Americas:
BGI Americas, headquartered in Cambridge, MA, was founded in 2010. BGI Americas has established partnerships and collaborations with leading American academic and governmental research institutions as well as global biotechnology and pharmaceutical companies. Among the more recent partnerships and collaborations entered into by BGI Americas include: • Partnership with Children’s Hospital of Philadelphia, BGI@CHOP, to conduct large-scale human genome sequencing and bioinformatics analysis at a newly established, state-of-the-art Joint Genome Center at CHOP.
OPKO Health:
OPKO Health, Inc. is a multi-national pharmaceutical and diagnostics company that aims to establish industry-leading positions in large and rapidly growing medical markets by leveraging our discovery, development, and commercialization expertise and our novel and proprietary technologies. We intend to leverage our global commercialization
Gennxeix Biotech Inc:
Gennxeix Biotech Software Inc Genomics we are creating genomic-driven commercial solutions to revolutionize many industries. We have started by focusing on energy, but we imagine a future where our science could be used to produce a variety of products, from synthetically derived vaccines to prevent human diseases to efficient cost effective ways to create clean drinking water. The world is dependent on science and we're leading the way in turning novel science into life-changing solutions.
What these companies are doing is taking medicine to the next level. From Alzheimer , Breast Cancer to Diabetes they are using your genes to determined if you have one or many diseases. This Process is called Genomics. Yes we are in the genomics revaluation. We know with breast cancer up to 50 percent of the patients get chemotherapy that do not need. In stead of lumping treatment decisions in to one modis of care Doctors now can pin point to a Cure.
A example of this discovery of the genes that contribute to these pathophysiologies when deregulated by recurrent aberrations is important to understanding mechanisms of cancer formation and progression and to guide improvements in cancer diagnosis and treatment. Electronic Medical Records Gennxeix is also key in a cure for breast cancer. What the fust is all
The new classifications - four types called HER2 "enriched," luminal A, luminal B and basal-like - categorize breast cancers by their genomic structure using a dizzying array of data points not previously available that have identified new pathways for the cancer to do its damage, making it possible for researchers to identify new places to target disease.
Brought To You By Antiques of River Oaks Houston,Tx In what could be seen as the most promising development of this breast cancer study, researchers determined that some basal-like cancers had more in common with an aggressive form of ovarian cancer known as "serous" than with other types of breast cancer. Two other types of breast cancer, accounting for most cases of the disease, arise from the luminal cells that line milk ducts. These cancers have proteins on their surfaces that grab estrogen, fueling their growth. Just about everyone with estrogen-fueled cancer gets the same treatment. Some do well. Others do not. The genetic analysis divided luminal cancers into two distinct subtypes. The luminal
A subtype had good prognoses while luminal B did not, suggesting that perhaps patients with luminal A tumors might do well with just hormonal therapy to block estrogen from spurring their cancers while luminal B patients might do better with chemotherapy in addition to hormonal therapy. In some cases, genetic aberrations were so strongly associated with one or the other luminal subtype that they appeared to be the actual cause of the cancer. The better News is that Genomics is on the Clock. Genomics provide a faster cheaper more effective way to detect the Her2 gene by using Semiconductor Sequencing. A example of this technique is Hybrid Pharma Gennxeix Semiconductor Sequencing. "Quantum Theory" In Action for Breast Cancer Patients. A polymerase is an enzyme whose central function is associated with polymers of nucleic acids such as RNA and DNA. The primary function of a polymerase is the polymerization of new DNA or RNA against an existing DNA or RNA template in the processes of replication and transcription. In association with a Hybrid Pharma Gennxeix also uses a Visualize Real-Time Breast Cancer Data using Signal Stochastic Resonance Units Neurons Detection and Analysis for Breast Cancer model after McCulloch-Pitts.Hybrid Pharma computer-assisted diagnosing of breast cancer from mammograms. Hybrid Pharma works is a genetic network simulation trained with tumor incidence data from knockout experiments. Gennxeix Biotech uses Semiconductor Sequencing Chips that create a direct connection between Biochemical and digital information, bringing these two languages together. Hybrid's chips are designed like any other semiconductor chips. Pairing proprietary semiconductor technology with sequencing chemistry a nucleotide is incorporated into a strand of DNA by a polymerase, a hydrogen ion is released. Gennxeix Biotech used a high-density array of micro-machined wells for bioctechnology process in a massive way. Each well holds a different DNA template. Beneath the wells is an ion-sensitive layer and beneath that a proprietary Ion sensor. HER2 in many patients respond differently. Genomics can be the GPS to Extend life in Breast Cancer Patients. formalin fixed, paraffin embedded techniques and Her-2 Approximately Where do you really come from? And how can this information Solve Breast Cancer? Approximately 30% of malignant breast cancers demonstrate overamplification of the human epidermal receptor type 2 (HER2) gene. HER-2 can be resistant to low-doses of anthracycline-based Hybrid Pharma have demonstrated that they can be used to map DNase (deoxyribonuclease) DNA origins of replication. Hybrid Pharma Recent progress in microarray technology has been related to the development of high resolution microarrays which can map genomic alterations and constitutional variants in DNA copy number at an extremely high resolution for Breast Cancer chemotherapy. formalin fixed, paraffin embedded techniques and Her-2The Good News is that science has advanced. Sections of microarray provide targets for parallel in situ detection of DNA, RNA and protein targets in each specimen on the array. The better News is that Genomics is on the Clock. Genomics provide a faster cheaper more effective way to detect the Her2 gene by using Semiconductor Sequencing. A example of this technique is Hybrid Pharma Semiconductor Sequencing. "Quantum Theory" In Action for Breast Cancer Patients. A polymerase is an enzyme whose central function is associated with polymers of nucleic acids such as RNA and DNA. The primary function of a polymerase is the polymerization of new DNA or RNA against an existing DNA RNA template in the processes of replication and transcription. In association with a Hybrid Pharma also uses a Visualize Real-Time Breast Cancer Data using Signal Stochastic Resonance Units Neurons Detection and Analysis for Breast Cancer model after McCulloch-Pitts. Hybrid Pharma computer-assisted diagnosing of breast cancer from mammograms. Hybrid Pharma Gennxeix works is a genetic network simulation trained with tumor incidence data from knockout experiments. Gennxeix Biotech uses Semiconductor Sequencing Chips that create a direct connection between Biochemical and digital information, bringing these two languages together. Hybrid's chips are designed like any other semiconductor chips. Pairing proprietary semiconductor technology with sequencing chemistry a nucleotide is incorporated into a strand of DNA by a polymerase, a hydrogen ion is released. Gennxeix Biotech used a high-density array of micro-machined wells for bioctechnology process in a massive way. Each well holds a different DNA template. Beneath the wells is an ion-sensitive layer and beneath that a proprietary Ion sensor. HER2 in many patients response differently. Genomics is the GPS to Extend life in Breast Cancer Patients
No comments:
Post a Comment